期刊名称：ESC HEART FAILURE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Overview
ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology; it is dedicated to the advancement of knowledge in the field of heart failure management.
Aims and Scope
ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
Readership
Cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focussing on cardiovascular research, and those working in rehabilitation.
Keywords
Heart failure; ESC Heart Failure; international journal; open access; European Society of Cardiology; Heart Failure Association; acute heart failure; arrhythmias; devices; renal dysfunction; epidemiology; autonomic function; invasive cardiology; PET; heart transplantation; diabetes; cardio-thoracic surgery; anemia; echocardiography; congenital heart disease; prevention; treatment; molecular and cellular biology; pathology; physiology; electrophysiology; pharmacology; population science; nursing; care of the elderly; primary care; health economics; cardiovascular research
Abstracting and Indexing Information
- Current Contents: Clinical Medicine (Clarivate Analytics)
- Embase (Elsevier)
- MEDLINE/PubMed (NLM)
- PubMed via PMC deposit (NLM)
- Science Citation Index Expanded (Clarivate Analytics)
- SCOPUS (Elsevier)
- Web of Science (Clarivate Analytics)
Instructions to Authors
INTRODUCTION
Thank you for your interest in ESC Heart Failure. Please consult the following instructions for help in preparing your manuscript, and feel free to contact us with any questions. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review. We look forward to reviewing your submission.
HEART NETWORK
ESC Heart Failure participates in the HEART Network, which is a network of Editors from most cardiovascular journals. Information is exchanged between Editors on a regular basis. The network has recently approved a common ethics standard. Its purpose is to ensure transparency and honesty in the scientific process that promotes ethical conduct in performance and publication of research.
The following will be considered as parts of this process:
a. Disclosure of potential conflicts of interest for all involved in the performance of research and in the evaluation and publication process of a manuscript. Relevant relationships with commercial interests should be disclosed according to the guidelines of the journal's sponsoring society, or, when no such guidelines exist, according to those of the AHA, ACC, or ESC.
b. Establish thorough review processes particularly alert to discovering scientific fraud and data falsification, redundant or duplicate publication, and plagiarism, and to adopt a uniform standard of dealing with authors guilty of fraudulent practices.
c. To maintain confidentiality and embargos where appropriate.
d. To create uniform criteria to establish authorship. To qualify for authorship, individuals must have made substantial contributions to the intellectual content of the paper in at least one of the following areas: conceived and designed the research, acquired the data, analysed and interpreted the data, performed statistical analysis, handled funding and supervision, drafted the manuscript, or made critical revision of the manuscript for important intellectual content. Authors must give final approval of the version to be submitted and any revised version to be published. For multi-centre trials, individuals who accept direct responsibility for the manuscript should fully meet the criteria for authorship defined above and contributors not meeting these criteria should be acknowledged.
e. Avoidance of false claims of ownership, priority, by attention to previous publications.
f. Avoidance of excessive claims of benefits of a product/technique, in the publication as well as with news media.
g. Noting compliance with institutional review board requirements and, when appropriate, approved laboratory procedures for animal research, and that the research conforms to the ethical standards of the Declaration of Helsinki, the Geneva Declaration, the Belmont Report, and Good Clinical Practices from the FDA, and the submission conforms to the International Committee of Medical Journal Editors (ICMJE): Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication (Haematologica 2005; 89:264).
PRE-SUBMISSION
1. Editorial Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two anonymous reviewers and the Editor. Final acceptance or rejection rests with the Editorial Board, who reserves the right to refuse any material for publication.
Manuscripts should be in a clear, concise and direct style. Where contributions are judged as acceptable for publication on the basis of content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.
2. Pre-submission Resources
2.1. Author Services
Prior to submission, we encourage you to browse the ‘Author Resources’ section of the Wiley Author Services website: http://authorservices.wiley.com/bauthor/author.asp.
This site includes useful information on copyright matters, ethics, electronic artwork guidelines, and how to optimise your article for discovery by search engines.
2.2. Pre-submission English-language Editing
Authors for whom English is a second language are advised to consider having their manuscript professionally edited before submission to improve the English, and to ensure the paper is clearly written in standard, scientific English language appropriate to the discipline. This can be undertaken by a service such as the Wiley English Language Editing Service, at http://wileyeditingservices.com.Please note that using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal, and all services are paid for and arranged by the author.
3. Manuscript Preparation
3.1. Manuscript Categories and Criteria
ESC Heart Failure accepts the following categories of articles:
Original Research Articles
Open Access journals are less stringent when it comes to article length, particularly for those articles published online only. Nevertheless, we encourage that original articles do not exceed 5000 words (excluding references, tables and figures) and may include up to a maximum of 8 figures and/or tables and up to 50 references. For articles considered to be published in our print issues, we suggest that only 3500 words and 40 references and 6 figures and/or tables are provided. Full length articles should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Funding, (9) Declaration of interest, (10) References, (11) Figure legends, (12) Appendices, (13) Tables, (14) Figures. The Abstract should be divided into the following sections 'Aims', 'Methods and results' and 'Conclusions'; it should not exceed 400 words.
Reviews
ESC Heart Failure publishes a limited number of scholarly, comprehensive review papers. Short Reviews should not exceed 3500 words (excluding references, tables and figures), and may include up to 50 references. Comprehensive (i.e. systematic) reviews are typically published online only should not exceed 6000 words (excluding references, tables and figures), and may include up to 120-150 references. All reviews should summarise and critically evaluate research in the subject area, and should discuss implications for the future. Reviews have unstructured abstracts with no headings, which should not exceed 400 words.
Editorials
All editorials should be limited to 1500 words (excluding references), with a maximum of 15 references. We require that all editorials have an abstract of 150-200 words.
Short Communication
These reports should not exceed 1500 words and should comprise a Background section (≈100 words), Aims (≈50 words), Methods (≈300 words), Results (300 words) and Conclusions (250 words). The editorial team reserves the right to decide which of the tables/figures submitted are necessary. A structured abstract not exceeding 400 words is also required.
Letters to the Editor
Relevant correspondence will be considered. This should not exceed 400 words in length excluding references. A maximum of 10 references are permitted.
Case Reports
These reports should not exceed 1500 words and 15 references. Case reports should include an unstructured Abstract with no subheadings (not exceeding 150 words), an Introduction, a Description of the case(s) under the heading, ‘Case Report’ and a Discussion of the findings in the context of current practice.
Study Design
These should not exceed 3500 words (excluding references, tables, and figures) and may include up to a maximum of 6 figures and/or tables and up to 50 references. Study design papers should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Study Design, (5) Discussion, (6) Acknowledgements, (7) Funding, (8) Declaration of Interest, (9) References, (10) Figure legends, (11) Appendices, (12) Tables, (13) Figures. The Abstract should be divided into the following sections ‘Aims’, ‘Methods’, and ‘Conclusions’; it should not exceed 400 words.
3.2. Manuscript Format and Structure
General Format
Prepare your manuscript text using a Word processing package (save in .doc or .rtf format). Submissions of text in the form of PDF files are not permitted. Manuscripts should be double-spaced, including text, tables, legends and references.
Number each page. Please avoid footnotes; use instead, and as sparingly as possible, notes within brackets. Enter text in the style and order of the journal. Type references in the correct order and style of the journal. Type unjustified, without hyphenation, except for compound words (where two words are joined to form a new word e.g. end-systolic, non-infarcted). Type headings in the style of the journal. Use the TAB key once for paragraph indents. Where possible use Times New Roman for the text font and Symbol for Greek and special characters. Use the word processing formatting features to indicate bold, italic, Greek, maths, superscript and subscript characters. Clearly identify unusual symbols and Greek letters. Differentiate between the letter O and zero; the letters I and l; and the number 1.
Check the final copy of your paper carefully, as any spelling mistakes and errors may be translated into the typeset version.
Style and Spelling
Oxford English spelling should be used. Authors whose first language is not English are requested to have their manuscripts checked carefully by a native speaker before submission. This will help expedite the review process and avoid confusion.
Abbreviations
Abbreviations of standard SI units of measurement only should be used.
Ethics
Declaration of Helsinki: The authors should state their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their guardians).
ARRIVE Guidelines: The contribution of animal research in enabling better health for man and animals is incontrovertible and ESCHF is committed to the publication of research studies which use animal models, but demands the same rigorous attention to detail as in clinical trials. Failure to describe research methods and to report results appropriately has scientific and ethical implications for the entire research process and the reputation of those involved in it.
Experiments involving animals should be appropriately designed, correctly analysed and then transparently reported, to both increase the validity of the results, and maximise the scientific gain. A minimum amount of relevant information must be included in manuscripts published in this journal to ensure that the methods and results of a study can be reviewed, analysed and repeated. ESCHF will therefore refer to the ARRIVE (Animals in Research: Reporting In Vivo Experiments) Guidelines as the basis for the process of reviewing manuscripts of research involving animals.
These guidelines were generated by The National Centre for the Replacement, Refinement and Reduction of Animals in Research, which is an independent scientific organisation, established by the UK Government, in consultation with scientists, statisticians, journal editors and research funders.
COPE: Wiley provides the Editors of ESCHF with membership of the Committee On Publication Ethicsand the Editors use their Codes of Conduct and flowcharts as a guide in dealing with publication ethics issues.
Wiley’s Best Practice Guidelines on Publishing Ethics: The Editors of ESCHF are supported by Wiley’s Best Practice Guidelines on Publishing Ethics: A Publisher's Perspective. Second Edition, in dealing with publication ethics issues, and it forms the basis of the journal’s ethics policy.
Cover Letter for Submission to ESC Heart Failure & Declaration on Ethical Publishing
It is the aim of the Editorial Team of ESC Heart Failure to promote high academic standards, transparency and ethical publishing. Therefore, all authors aiming to publish in ESC Heart Failure are requested to state in the article’s cover letter that they have adhered to the journal’s ethics policies by stating “The authors of this manuscript comply with the ethics policies of ESC Heart Failure as stated in the ESC Heart Failure Author Guidelines on its website”. [1]
By submitting an article for publication to ESC Heart Failure, in the cover letter the corresponding author, on behalf of all co-authors,
- certifies that all authors listed on the manuscript have approved its submission and publication as provided to ESC Heart Failure;
- certifies that no person who has a right to be recognized as author has been omitted from the list of authors;
- certifies each author has made an independent material contribution to the work submitted for publication;
- certifies that the submitted work is original and is neither under consideration elsewhere nor has it been published previously in whole or in part other than in abstract form;
- certifies that for all original studies have been approved by relevant bodies such as institutional review boards or ethics committees. This rule is not applicable for review articles or editorial comments that give reference to other people’s work;
- certifies that all conflicts of interest, financial or otherwise, that may affect the authors’ ability to present data objectively, have been duly declared in the manuscript;
- understands that the manuscript in its published form will be maintained on the servers of ESC Heart Failure as a valid publication only as long as all statements in the guidelines on ethical publishing remain true;
- understands that if any of the aforementioned statements ceases to be true the authors have a duty to notify the Editors of ESC Heart Failure as soon as possible so that the manuscript can be withdrawn.
DNA Sequences and GenBank Accession Number
For each and every gene accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the accession number should always be capitalised. Example: (GenBank accession nos. AI631510, AI631511, AI632198 and BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117).
3.3. Parts of the Manuscript
Title Page
The title page should include the following: (1) the title, (2) the name(s) of authors, (3) the institution(s) where work was performed, (4) the position, institution and location of all authors, (5) the telephone number, fax number and e-mail address of the corresponding author (6) the institutional affiliations of the authors (including corporate appointments) should be acknowledged in a footnote.
Abstract and Keywords
All abstracts may not contain more than 250 words and should be submitted as a separate file. The abstract should be formatted with the following heading: (1) Aims, (2) Methods and Results, (3) Conclusions.
A maximum of six keywords may be submitted.
Introduction
This section should provide a rationale for conducting the study within the context of previous work by other authors.
Methods
This section should be sufficiently detailed to enable repetition of the study by other investigators. If pertinent, the section may be divided into headed subsections. For animal studies, this section should contain a statement that, “The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985)”. Human studies should contain a statement that, “The investigation conforms with the principles outlined in the Declaration of Helsinki” (Br Med J 1964; ii: 177). In addition details of the ethics committee approval procedures and a statement that all subjects gave written informed consent to participate in the study should be included.
Statistics: All manuscripts selected for publication will be reviewed for the appropriateness and accuracy of the statistical methods used and the interpretation of statistical results. All papers submitted should provide in their Methods section a subsection detailing the statistical methods, including the specific method used to summarize the data, the methods used to test their hypothesis testing and (if any) the level of significance used for hypothesis testing.
Results
If pertinent, the section may be divided into headed subsections. For presentation of data, figures are preferred to tables. Data should not be duplicated in both figures and tables. Extensive numerical data should be presented in legends to the figures rather than in the main body of text. SI units should be used throughout.
Discussion
Four manuscript pages should in general be enough to compare and interpret the findings of the study with regard to previous work by (other) authors. This section should also contain 1–4 paragraphs dealing with topics that are beyond the scope of the study. Limitations to the study should also be discussed.
Figures
All illustrations (line drawings and photographs) are classified as figures. The review process will not begin until all figures are received. Figures should be limited to the number necessary for clarity and must not duplicate data given in tables or in the text. They must be suitable for high quality reproduction and should be submitted in the desired final printed size so that reduction can be avoided. Figures should be no larger than 125 (height) x 180 (width) mm (5 x 7 inches) and should be submitted in a separate file from that of the manuscript. More information about figures is available on Author Services at: http://media.wiley.com/assets/7323/92/electronic_artwork_guidelines.pdf.
We need to receive your figures in electronic form. To minimise publication time of your manuscript and help you achieve the optimum quality for your published figures it is important that all electronic artwork is supplied in the correct format and resolution. Please save vector graphics (e.g. line artwork) in EPS format at 600 dpi, and bitmap files (e.g. half-tones) in TIFF format at 300 dpi.
We recommend that you consult the Electronic Artwork Guidelines athttps://authorservices.wiley.com/asset/photos/electronic_artwork_guidelines.pdf
Line Drawings: Please provide these as clear, sharp illustrations, suitable for reproduction as submitted. All labelling should be on the original. Faint and grey shading or stippling will be lost upon reproduction and should be avoided. Where various shadings are used within one figure please ensure that it is easy to differentiate between them, using standard shadings (see the hard copy of the journal for examples). There should be sufficient white space between lines and dots to ensure the areas will not fill in and look grey. If stippling is used, this should be made up of clear black dots with visible white space between them.
Ensure that the size of the lettering is in proportion with the overall dimensions of the drawing. Ideally, the drawings should be submitted in the desired final printed size to avoid reduction. If submitting line drawings which require reduction, please check that the lettering will be clearly legible after the drawing has been reduced to the size at which it will be printed. After reduction, letters should not be smaller than 2 mm in height.
Photographs: Photographs should be of sufficiently high quality with respect to detail, contrast and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Please indicate the magnification by a rule on the photograph.
Figure Legends
These should be on a separate, numbered page, and grouped under the heading "Legends". Define all symbols and abbreviations used in the figure. Common abbreviations and others in the preceding text should not be redefined in the legend.
Tables
Tables should be typed with double spacing, but minimising redundant space, and each should be placed on a separate sheet. Tables should be submitted, wherever possible, in a portrait, as opposed to landscape, layout. Each Table should be numbered in sequence using Arabic numerals. Tables should also have a title above and an explanatory footnote below. All abbreviations used should be defined in the footnote. NB: tables must be submitted in an editable format, such as Excel or Word, and not embedded as an image or presented as an image file.
Permissions
If any figures are to be duplicated from previously published work, written permission must be obtained both from the publisher and the author, and a credit line giving the source added to the relevant figure legend. If text material (250 to 300 words) is to be reproduced from published sources, written permission is required from both publisher and author. For shorter quotations, it is sufficient to add a bibliographic credit. The Letters containing the permission for the reproduction of either text or illustrations must be uploaded with the manuscript files. If you have been unable to obtain permission, please indicate this.
If no permissions are required, submit a Word document with your figure stating this, please.
Sources of Funding
Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.
The following rules should be followed:
- The sentence should begin: ‘This work was supported by …’
- The full official funding agency name should be given, for example ‘the National Cancer Institute at the National Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 sub-institutions) or 'NCI at NIH’.
- Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
- Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
- Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].
Acknowledgements
Substantive contributions of individuals, who do not qualify for authorship status should be noted in the Acknowledgements, positioned before the Declaration of Interest statement.
Declaration of Interest
All authors must make a formal declaration of interest that should include all issues that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such declarations might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. Also major grants in the field studied and other interests should be mentioned. The statement should be positioned before the list of references. If there are no interests to declare, please insert the wording, ‘Declaration of Interest: none declared’.
Citing References in ESC Heart Failure
References should be identified in the text by Arabic numerals and numbered in the order cited. All references should be compiled at the end of the article in the Vancouver style, except that ALL authors should be listed.
Complete information should be given for each reference including the title of the article, abbreviated journal title and page numbers.
Personal communications, manuscripts in preparation and other unpublished data should not be cited in the reference list but may be mentioned in parentheses in the text. Authors should get permission from the source to cite unpublished data. Titles of journals should be abbreviated in accordance with Index Medicus (see list printed annually in the January issue of Index Medicus). If a journal is not listed in Index Medicus then its name should be written out in full.
We recommend the use of a tool such as EndNote or Reference Manager for reference management and formatting. EndNote reference styles can be searched for here: http://www.endnote.com/support/enstyles.asp. Reference Manager reference styles can be searched for here: http://www.refman.com/support/rmstyles.asp.
Article Citation Example:
1. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006; 8:532-538.
If an article has been published online but has not yet been given issue or page numbers please use the Digital Object Identifier (doi) number when referencing the article as in the example below:
2. Asger A, Møller JM, Daugaard PC, Kjær SU, Erik S. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail;doi:10.1016/j.eheart.2008.09.016. Published online ahead of print 12 March 2008. Chapter Citation Example:
3. Nichols WW, O'Rourke MF. Aging, high blood pressure and disease in humans. In: Arnold E, ed. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London/Melbourne/Auckland: Lea and Febiger; 1990. p. 398-420. Website Citation Example:
4. Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14. http://www.ifcc.org/ejifcc/vol14no2/1402062003014n.htm (28 May 2004).; where the date in parentheses refers to the access date. Supporting Information Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material should be submitted at the same time as the main manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and file sizes are acceptable can be found at http://authorservices.wiley.com/bauthor/suppmat.asp. Please note that supporting information will be assessed critically by reviewers and editors and will only be accepted if it adds value to the paper. Supporting information should not contain data that are critical to the paper.
SUBMISSION OF MANUSCRIPTS
ESC Heart Failure uses a web-based submission and review system at http://www.editorialmanager.com/eschf/default.aspx. Online submission facilitates the submission of manuscripts from authors and streamlines the reviewing and publication process.
Authors may send queries concerning the submission process to eschf.editorialoffice@wiley.com. For enquiries about the review process and journal procedures, the editorial office can be contacted at Monika Diek, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany, Email: eschf.editorialoffice@wiley.com, Tel: +49 (0)30-450 553 407. Once you have prepared your manuscript according to these instructions, please go to the online submission system. First-time users must click ‘Create Account’ on the navigation menu at the top right of the screen. The system will send an automatic reminder e-mail with the user name and password you choose. Detailed guides for authors and reviewers are available at the submission site.
4. Submission Requirements
Each submission must include a covering letter, a declaration of interest statement.
Short Title: Published papers include a running header (max. 50 characters), which is a shortened version of the article title. Please insert a suggested short title in the ‘Running head’ field on the submission screen.
4.1. Covering Letter
The covering letter should include the following:
- a declaration that ‘the manuscript, or part of it, has neither been published (except in the form of abstract or thesis) nor is currently under consideration for publication by any other journal’;
- an explanation as to why your paper would be of particular interest to the readers of the ESC Heart Failure;
- a statement declaring that all named authors have seen and approved the final version of the manuscript.
4.2. Declaration of Interest
When first submitting, in the manuscript a declaration of interest for all authors must be made. Before acceptance, a formal and signed declaration of interest must be provided indicating any potential conflict of interest and any other statement that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. They also include major grants on the subject under research from public or commercial entities.
ESC Heart Failure follows the guidelines of the International Committee of Medical Journal Editors. A declaration of interest statement must be included in the manuscript after any ‘Acknowledgements’ and ‘Funding’ sections. If there is no conflict of interest, authors must include ‘Declaration of Interest: none declared’. Submissions that do not include this section will not be sent for peer review.
POST-ACCEPTANCE
5. Author Services
Online production tracking is available for your article through Wiley's Author Services. Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/default.asp for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
6. Open Access Agreements
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
As an Open Access journal, ESC Heart Failure offers the corresponding authors a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
Creative Commons Attribution License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
7. Proof Corrections
The corresponding author will receive an e-mail alert containing a link to a website. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site.
Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the Adobe website. This will enable the file to be opened, read on screen, and any corrections to be added in. Further instructions will be sent with the proof.
8. Early View (Online Publication Prior to Print)
Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are the version of record and are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. As they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
9. Author Material Archival Policy
Please note that unless specifically requested, Wiley will dispose of all hardcopy or electronic material submitted two months after publication. If you require the return of any material submitted, please inform the or production editor as soon as possible.
OTHER INFORMATION
10. Reprints
As this is an open access journal, you have free, unlimited access to your article online. However, if you wish to obtain printed reprints, these may be ordered online: www.sheridan.com/wiley/eoc
11. Online
Visit the ESC Heart Failure home page at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2055-5822 to read articles and issues, to sign up for e-Table of Contents alerts and for more information about the journal. Check Wiley’s Author Services pages for submission tips and guides and digital graphics standards.
12. Contact the Editorial Office
Monika Diek, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany, Email: eschf.editorialoffice@wiley.com, Tel: +49 (0)30-450 553 407.
13. References
1. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2010; 1:7-8.
Editorial Board
EDITOR-IN-CHIEF
Prof. Stefan D Anker
Berlin, Germany
DEPUTY EDITORS
Stephan von Haehling - Clinical
Goettingen, Germany
Zoltan Papp - Basic Science
Debrecen, Hungary
EDITORIAL OFFICE
Monika Diek, Anja Janssen
Email: eschf.editorialoffice@wiley.com
STATISTICAL EDITOR
Alexander Krannich
Berlin, Germany
ASSOCIATE EDITORS
Philip Adamson
Austin, TX, USA
Ali Ahmed
Washington, DC, USA
Ahmad Amin
Tehran, Iran
Boris Bigalke
Berlin, Germany
Yuksel Cavusoglu
Eskisehir, Turkey
Vijay Chopra
Haryana, India
Andrew Coats
Melbourne, Australia
Wolfram Doehner
Berlin, Germany
Frank Edelmann
Berlin, Germany
Dimitrios Farmakis
Athens, Greece
Gabor Földes
London, United Kingdom
Lutz Frankenstein
Heidelberg, Germany
Plamen Gatzov
Sofia, Bulgaria
Nazha Hamdani
Bochum, Germany
Denise Hilfiker-Kleiner
Hannover, Germany
Haruki Itoh
Tokyo, Japan
Tiny Jaarsma
Linköping, Sweden
Ewa Jankowska
Wroclaw, Poland
Mahir Karakas
Hamburg, Germany
Till Keller
Frankfurt/Main, Germany
Mitja Lainscak
Murska Sobota, Slovenia
Carolyn Lam
Singapore, Singapore
Wayne Levy
Seattle, WA, USA
Alexander Lyon
London, United Kingdom
Christian Müller
Basel, Switzerland
Michel Noutsias
Jena, Germany
W. Frank Peacock
Houston, USA
Massimo Piepoli
Piacenza, Italy
Ileana L. Piña
The Bronx, NY, USA
Bertram Pitt
Ann Arbor, USA
Bruno Podesser
Vienna, Austria
Tamás Radovits
Budapest, Hungary
P. Christian Schulze
Jena, Germany
Karen Sliwa-Hähnle
Cape Town, South Africa
Jochen Springer
Göttingen, Germany
Martin Šterba
Prague, Czech Republic
Thomas Thum
Hannover, Germany
Ali Vazir
London, United Kingdom
M. Birhan Yilmaz
Sivas, Turkey
Tanja Zeller
Hamburg, Germany
EDITORIAL BOARD
Magdy Abdelhamid
Cairo, Egypt
Johann Bauersachs
Hannover, Germany
John Cleland
London, United Kingdom
Gerasimos Filippatos
Athens University, Athens, Greece
Thomas L. Force
Nashville, USA
Gerd Hasenfuß
Göttingen, Germany
Arno W. Hoes
Utrecht, The Netherlands
Douglas L. Mann
St Louis, USA
Theresa McDonagh
London, United Kingdom
Walter J. Paulus
Amsterdam, The Netherlands
Hani N. Sabbah
Detroit, USA
Burkert Pieske
Berlin, Germany
Piotr Ponikowski
Wroclaw, Poland
Giuseppe Rosano
Rome, Italy
Evgeny Shlyakhto
St. Petersburg, Russia
Carsten Tschöpe
Berlin, Germany
| 
